1. 1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Issue 3 (September 2015) Authors: Zielinski, C.C.; Lang, I.; Inbar, M.; Kahan, Z.; Greil, R.; Beslija, S.; Stemmer, S.M.; Zvirbule, Z.; Steger, G.G.; Melichar, B.; Pienkowski, T.; Sirbu, D.; Petruzelka, L.; Eniu, A.; Nisenbaum, B.; Dank, M.; Anghel, R.; Messinger, D.; Brodowicz, T. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S263 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Decision impact of the 21-Gene Oncotype DX Recurrence Score Assay® in the Czech Republic on recommendations for adjuvant chemotherapy in estrogen receptor positive early stage breast cancer (ESBC) patients. (March 2019) Authors: Petrakova, K.; Petruzelka, L.; Holanek, M.; Svoboda, T.; Benesova, V.; Palacova, M.; Kolarova, I.; Bielcikova, Z.; Chrapava, M. Journal: Breast Issue: Volume 44(2019)Supplement 1 Page Start: S16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Molecular analysis of JAK2 gene in patients with triple negative breast cancer in relation to disease prognosis – a pilot study. (March 2017) Authors: Stanek, L.; Tesarova, P.; Vocka, M.; Musil, Z.; Petruzelka, L. Journal: Breast Issue: Volume 32(2017)Supplement 1 Page Start: S46 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Mutations in K-ras and c-erbB2 expression in pancreatic cancer samples from archival tissue samples. (October 2000) Authors: Kleihl, Z.; Novotny, J.; Vedralova, J.; Petruzelka, L.; Pohlreich, P.; Matous, B.; Stribrna, J.; Janku, F. Journal: Biochemical Society transactions Issue: Volume 28:Number 5(2000) Page Start: A222 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Neoadjuvant Trastuzumab in HER2+ early breast cancer patients – one clinic experience. (March 2017) Authors: Petruzelka, L.; Bielcikova, Z.; Zimovjanova, M.; Tesarova, P.; Pribylova, J.; Hejduk, K.; Chloupkova, R. Journal: Breast Issue: Volume 32(2017)Supplement 1 Page Start: S78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Preventive programme for carriers of genetic alteration in BRCA1/2 and other high-risk genes. Czech single institution evaluation -fifteen years experience. (April 2018) Authors: Zimovjanova, M.; Bielčikova, Z.; Miskovicova, M.; Petruzelka, L. Journal: European journal of cancer Issue: Volume 92(2018)Supplement 3 Page Start: S144 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗